INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH

ISSN(print): 2833-213X, ISSN(online): 2833-2148

Volume 04 Issue 01 January 2025

DOI : 10.58806/ijhmr.2025.v4i1n05

Page No. 22-26

Histopathological Changes in Pancreatic Cancer: A Review Article

Sawsam Jaseim Al-Harbi[1], Ali A. Al-fahham[2]

[1] Department of Human Anatomy, College of Medicine, University of Babylon, Iraq

[2] Faculty of Nursing, University of Kufa, Iraq

ABSTRACT: Pancreatic cancer is one of the most fatal neoplasias worldwide due to diagnosis at a late stage and poor rates of survival. A highly aggressive neoplasm induces profound histopathological changes and complexity in the microenvironment of the tumor. This review synthesizes recent research findings on the histopathological changes associated with pancreatic cancer, highlights knowledge gaps, and suggests future directions for research. Pancreatic ductal adenocarcinoma is an extremely malignant form of cancer characterized by increased incidence rates and very low rates of survival. Increasing attention to aspects related to risk factors, diagnostics, treatment, and outcomes is becoming mandatory. The present review synthesizes the existing research findings on the etiology of pancreatic cancer, focusing on the main elevated risk factors and genetic sources that explain the histopathological shifts produced during all stages of the illness.

KEYWORDS: Pathophysiology, Etiology, Pancreatic Cancer, PDAC

INTRODUCTION

Pancreatic cancer, in particular pancreatic ductal adenocarcinoma (PDAC), is an aggressive solid tumor that demonstrates marked histopathological changes and complexity in the tumor microenvironment. The interactions between its epithelial and stromal components are key factors that drive both its pathobiology and therapeutic responsiveness influencing patient prognosis. To better understand the current advances in pancreatic cancer, further research is required to elucidate the current gaps in knowledge. A detailed evaluation of the burden of pancreatic disorders, among them acute and chronic pancreatitis, cannot be omitted when discussing pancreatic cancer. The role of life habits in this disease has been a noteworthy focal issue in studies by Yadav and Lowenfels (2013). These results clearly warrant attention to the changeable risk factors and smoking and alcohol-free lifestyles as recommended primary preventives. Rawla et al. (2019) also reinstated the influence of tobacco smoking, diabetes, obesity, and chronic pancreatitis as major risk factors. The importance of the need to know these factors is stressed by the fact that the survival rate is low for people diagnosed with pancreatic cancer, which of course strengthens the need for primary prevention efforts. In addition, disparities in incidence between racial groups on which data were available, with Afro-Americans having a high incidence, underlining how demographic factors can influence disease etiology (Yadav & Lowenfels, 2013).

Genetic factors contribute significantly to the etiology of pancreatic cancer. Ilic and Ilic (2016) put the RAS gene into much focus on mutations, specifically KRAS, a high-prevalence mutation in pancreatic ductal adenocarcinoma (PDAC). The contribution of genetic predisposition is expanded by Amrutkar and Gladhaug (2017) by throwing more light on familial aggregation involving a genetic base for susceptibility, where inherited traits have the capacity to make a significant contribution to the development of the disease. The increasing evidence supports the association of lifestyle factors, in particular, obesity and pancreatic cancer risk. New evidence of the link of obesity to cancer was surveyed by Maisonneuve and Lowenfels (2015), stressing the importance of the biological mechanisms through which such associations may be realized. At present, such a relationship gives prospects for lifestyle intervention to reduce the risk of pancreatic cancer. The findings of modifiable risk factors were also found by Witkiewicz et al. (2015) in their demand to better understand genetic diversity within this disease for possible therapeutic targets. It is only from a scrutiny of such myriad risk factors that one can start to get an appreciation of just how complex the issue of pancreatic cancer etiology is and the need for a comprehensive approach to prevention.

Identifying individuals at high risk for pancreatic cancer is under increased collective study. To further prove how screening techniques are inadequate to give early enough discovery of pancreatic lesions and subsequent possibilities for interventions, I agree with Waters and Der (2018) in their work on the importance of having effective methods of screening. An understanding of the risk factors would enhance the prevailing screening strategies that aim to improve outcomes among patients at risk. This relates to the argument by Maisonneuve and Lowenfels (2015), stressing important knowledge of neoplastic development from pancreatic lesions towards the objective of a review process— development of feasible preventive strategies based on an understanding of pancreatic cancer etiology. Therefore, specific early detection options need to be created and implemented.

Conclusively, besides the established risk factors and genetic associations, there exist enormous gaps in the understanding of pancreatic cancer etiology. Not only are there no specific targeted research studies focusing on mechanisms that drive racial disparities with their influence on pancreatic cancer outcomes, but also some interactions that throw future research towards demographic factors dependent on lifestyle and genetic risks. Histopathological knowledge relating to pancreatic cancer several lapses: even with the increased recognition of the influence of stroma and immune microenvironment on tumor progression and treatment response, specific molecular pathways in these mechanisms remain to be clarified. The influence of genetic heterogeneity also needs further investigation regarding its impact on histopathological features and treatment outcomes. Such questions demand a longitudinal research design tracking changes as tumors evolve throughout their proposed treatments. Advanced imaging can be integrated with histopathological assessments to gain ever deeper insights into the dynamic features of the tumor microenvironment. Exploring interactions between histopathological features and new therapeutic agents may bring to light potential biomarkers in forecasting treatment response and prognosis for such patients.

HISTOPATHOLOGICAL CHANGES

The tumor microenvironment in pancreatic cancer comprises predominantly a large stromal fraction, which hinders molecular classification and compromises tumor biology. In a study by Maurer et al. (2019), laser capture microdissection and RNA sequencing were applied to profile gene expression in PDA epithelium and stroma from matched pairs, finding a marked disparity in the proportion of these two tissues within cohorts. This diversity serves as evidence in support of the claim that the stroma plays a critical role in determining the molecular characteristics of the tumor, thus enforcing the notion that histopathological features must be considered in molecular classification systems for the enhancement of prognostic accuracy concerning treatment strategies.

The immune contexture in pancreatic cancer has been argued by Karamitopoulou (2019) to be driven by crosstalk between molecular and histopathological characteristics that may be biomarkers linked with patient outcome. Identified interrelation between such features has been brought to attention by Wartenberg et al. (2018) for Regulatory T cells and Tumor budding features, forecasting clinical outcome. Such observations underline the importance of the concurrent histopathological evaluation of immune and stromal elements of the tumor microenvironment.

Pancreatic ductal adenocarcinoma was detailed by Collisson et al. (2019) into discrete molecular subtypes that essentially correlate with specific histopathological features. Particularly, these features might as well be regarded to reflect the biological behavior and aggressiveness of the tumor—for example, influence from desmoplasia and immune cell infiltration. As Makohon-Moore et al. (2017) put it, limited diversity in known driver gene mutations among metastases may reflect that an understanding of the context dependent on histopathology may also provide insight regarding tumor evolution and mechanisms of therapy resistance.

Moncada et al. (2020) reports that spatial transcriptomics can be vital in understanding the tissue architecture of PDACs and therefore need to discuss the histopathological changes relating to the nature of the tumor. Such a finding gives a more specialized impression of how histopathological features truly impact gene expression profiles and, by extension, the behavior of the tumor. Precursor lesion identification is essential for understanding the histopathologic changes that evolve into invasive pancreatic cancer. As highlighted by Hidalgo et al. (2015), the morphological presentation and genetic alterations with these lesions raise the ultimate need for an early histopathologic examination to avert the progression of such lesions to invasive cancer.

However, the most direct evidence of the association of histopathological features with treatment outcomes is the unveiling of treatment studies. According to Wu et al. (2019), treatment efficacy as well as safety outcomes may be dependent on the histopathological features that underlie the condition. The results strongly proved further reasons as to why a histopathological examination should be forced into treatment planning for all patients. These findings further support evidence for triptolide inducing a reversal of epithelial-mesenchymal transition (EMT) and stem-like features in PDA, which has allowed its therapeutic effects to be enhanced through changes being directed in pathology.

Histopathological analysis of PDAC reveals highly stromal desmoplasia, mainly important for tumor progression, and immune cell infiltration. Thus, the dynamics of tumor stroma and immune cells were described regarding patient outcomes and the response to therapy. An observation by Mahajan et al. regarding some typical immune cell markers CD3, CD4, CD8 correlated with PFS may already serve to show how detailed histopathological assessment may qualify as a predictive factor for PDAC. Better recognition of precursor lesions: IPMNs and PanIN in the evaluation of morphological progression toward invasive PDAC. Wang et al. have recently classified the pathways from IPMNs to PDACs into de novo and sequential subtypes, a finding that highlights the increasing importance for earlier recognition by pathologists of these characteristic histological patterns.

A body of literature has uncovered substantial molecular and transcriptional heterogeneity within PDAC. A unifying paradigm was proposed by Hayashi et al. (2020) to return it into a coherent whole, positioning transcriptional heterogeneity in perspective with squamous features of PDAC, arguing that through histological characterization the biological behavior of the tumor can be defined. This underscores the importance of the role played by histopathology in appropriately classifying PDAC into biologically relevant categories that are capable, in turn, of guiding treatment strategies and improving prognostication.

Conversely, UC was recently described by Kalimuthu et al. (2019), which we consider to be a typical variant of PDAC. Undifferentiated Carcinoma with Osteoclast-like Giant Cells (UCOGC) genetic alterations it shares with standard PDAC. This

observation emphasizes the urgent need for careful histopathologic examination in which different variants should be distinct to ensure the right diagnosis and treatment approach.

Advanced imaging, especially radiomics and integration with histopathologic data, holds a promise of stepping toward the enhancement of diagnostic capability. Radiomics features may be able to capture subtle histological distinctions between PDAC and normal pancreatic tissue; hence, integration of these two modalities may appear to have achieved a breakthrough in early detection and proper patient management. The association of imaging findings with histopathological features, including but not limited to cellularity and stroma composition, becomes critical in the correct reading of imaging results.

CONCLUSION

In conclusion, pancreatic malignancy is an incredibly multifaceted illness regarding its etiology, involving several factors aspects of lifestyle, together with genetic and demographic influences. Though numerous risk factors continue to be identified on top of known risks, future research needs to fill the knowledge gap on how these factors interact to guide prevention strategies against this devastating disease with treatment shaped by those factors. Histopathological changes play a vital role in the biological behavior of PDAC. The behavior of Panthera-DAC, treatment response, and prognosis for patients depend on these changes. An upgrade in the outcomes for patients with pancreatic malignancy has to be tied to molecular classification and treatment design to involve that kind of change. Thereafter, more research in this area would promise better knowledge about the disease and improved therapeutic strategies. Histopathology of Pancreatic Ductal Adenocarcinoma is an integrative study that combines morphological analysis with molecular and immune profiling. Continued to emerge data continue to highlight the indispensable contribution of histopathology towards comprehending tumor biology and, therefore, informing therapeutic stratagems, which are both ultimate determinants of patient outcome.

REFERENCES

1) Amrutkar, M.., & Gladhaug, I.. (2017). Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers , 9 . http://doi.org/10.3390/cancers9110157
2) Bartsch, D.., Gress, T.., & Langer, P.. (2012). Familial pancreatic cancer—current knowledge. Nature Reviews Gastroenterology &Hepatology , 9 , 445-453 . http://doi.org/10.1038/nrgastro.2012.111
3) Choi, M.., Yoon, S.., Lee, Kyungjin., Song, Meiying., Lee, I.., Lee, Myung Ah., Hong, T.-H.., & Choi, Myung-Gyu. (2018). Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. Journal of Cachexia, Sarcopenia and Muscle , 9 , 326 - 334 . http://doi.org/10.1002/jcsm.12274
4) Chu, L.., Park, Seyoun., Kawamoto, S.., Fouladi, D.., Shayesteh, S.., Zinreich, E.., Graves, J.., Horton, K.., Hruban, R.., Yuille, A.., Kinzler, K.., Vogelstein, B.., & Fishman, E.. (2019). Utility of CT Radiomics Features in Differentiation of Pancreatic Ductal Adenocarcinoma From Normal Pancreatic Tissue.. AJR. American journal of roentgenology , 1-9 . http://doi.org/10.2214/AJR.18.20901
5) Collisson, E.., Bailey, Peter., Chang, D.., & Biankin, A.. (2019). Molecular subtypes of pancreatic cancer. Nature Reviews Gastroenterology & Hepatology , 16 , 207-220 . http://doi.org/10.1038/s41575-019-0109-y
6) Hidalgo, M.., Plaza, C.., Musteanu, M.., Illei, P.., Brachmann, C.., Heise, C.., Pierce, D.., López-Casas, P.., Menendez, C.., Tabernero, J.., Romano, A.., Wei, Xinyu., López-Rios, F.., & Hoff, D. V. Von. (2015). SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Clinical Cancer Research , 21 , 4811 - 4818 . http://doi.org/10.1158/1078-0432.CCR-14-3222
7) Ho, W. J.., Jaffee, E.., & Zheng, Lei. (2020). The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities. Nature Reviews Clinical Oncology , 1-14 . http://doi.org/10.1038/s41571-020-0363-5
8) Hoogstins, Charlotte E. S.., Boogerd, L.., BSc, Babs G. Sibinga Mulder., MD, PhD J. Sven D. Mieog., MD, PhD Rutger Jan Swijnenburg., MD, PhD Cornelis J. H. van de Velde., MD, PhD Arantza Farina Sarasqueta., MD, PhD Bert A. Bonsing., MSc, Berenice Framery., Pèlegrin, A.., Gutowski, M.., Cailler, F.., MD, PhD Jacobus Burggraaf., & MD, PhD Alexander L. Vahrmeijer. (2018). Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent. Annals of Surgical Oncology , 25 , 3350 - 3357 . http://doi.org/10.1245/s10434-018-6655-7
9) Ilic, M.., & Ilic, I.. (2016). Epidemiology of pancreatic cancer. World Journal of Gastroenterology , 22 , 9694 - 9705 . http://doi.org/10.3748/wjg.v22.i44.9694
10) Kalimuthu, S. N., Wilson, Gavin W.., Grant, R.., Seto, M.., O'Kane, G.., Vajpeyi, R.., Notta, F.., Gallinger, S.., & Chetty, R.. (2019). Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome. Gut , 69 , 317 - 328 . http://doi.org/10.1136/gutjnl-2019-318217
11) Kamisawa, T.., Takuma, K.., Egawa, N.., Tsuruta, K.., & Sasaki, Tsuneo. (2010). Autoimmune pancreatitis and IgG4-related sclerosing disease. Nature Reviews Gastroenterology &Hepatology , 7 , 401-409 .

http://doi.org/10.1038/nrgastro.2010.81

12) Karamitopoulou, E.. (2019). Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. British Journal of Cancer , 121 , 5 - 14 . http://doi.org/10.1038/s41416-019-0479-5
13) Katz, M.., Varadhachary, G.., Fleming, J.., Wolff, R.., Lee, Jeffrey E.., Pisters, P.., Vauthey, J.., Abdalla, E.., Sun, Charlotte C.., Wang, Huamin., Crane, C.., Lee, Jeffrey H.., Tamm, E.., Abbruzzese, J.., & Evans, Douglas B.. (2010). Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation. Annals of Surgical Oncology , 17 , 1794 - 1801 . http://doi.org/10.1245/s10434-010-0943-1
14) Klein, A.. (2021). Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nature Reviews Gastroenterology & Hepatology , 18 , 493 - 502 . http://doi.org/10.1038/s41575-021-00457-x
15) Liu, Li., Salnikov, A.., Bauer, Nathalie., Aleksandrowicz, E.., Labsch, S.., Nwaeburu, Clifford C.., Mattern, J.., Gladkich, J.., Schemmer, P.., Werner, J.., & Herr, I.. (2013). Triptolide reverses hypoxia-induced epithelial–mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. International Journal of Cancer. Journal International du Cancer , 134 , 2489 - 2503 . http://doi.org/10.1002/ijc.28583
16) Maisonneuve, P.., & Lowenfels, A.. (2015). Risk factors for pancreatic cancer: a summary review of meta-analytical studies.. International journal of epidemiology , 44 1 , 186-98 . http://doi.org/10.1093/ije/dyu240
17) Makohon-Moore, Alvin P.., Zhang, Ming., Reiter, Johannes G.., Bozic, I.., Allen, Benjamin., Kundu, Deepanjan., Chatterjee, K.., Wong, F.., Jiao, Y.., Kohutek, Z.., Hong, Jungeui., Attiyeh, M.., Javier, Breanna., Wood, L.., Hruban, R.., Nowak, M.., Papadopoulos, N.., Kinzler, K.., Vogelstein, B.., & Iacobuzio-Donahue, C.. (2017). Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nature Genetics , 49 , 358-366 . http://doi.org/10.1038/ng.3764
18) Maurer, Carlo., Holmstrom, Sam R.., He, Jing., Laise, P.., Su, T.., Ahmed, Aqeel., Hibshoosh, H.., Chabot, J.., Oberstein, P.., Sepulveda, A.., Genkinger, J.., Zhang, Jiapeng., Iuga, A.., Bansal, M.., Califano, A.., & Olive, K.. (2019). Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut , 68 , 1034 - 1043 . http://doi.org/10.1136/gutjnl-2018-317706
19) Moncada, Reuben., Barkley, Dalia., Wagner, F.., Chiodin, Marta., Devlin, J.., Baron, Maayan., Hajdu, C.., Simeone, D.., & Yanai, I.. (2020). Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nature Biotechnology , 38 , 333 - 342 . http://doi.org/10.1038/s41587-019-0392-8
20) Öberg, K.., & Castellano, D.. (2011). Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer and Metastasis Reviews , 30 , 3-7 . http://doi.org/10.1007/s10555-011-9292-1
21) Okumura, S.., Kaido, T.., Hamaguchi, Y.., Kobayashi, Atsushi., Shirai, Hisaya., Yao, Siyuan., Yagi, S.., Kamo, N.., Hatano, E.., Okajima, H.., Takaori, K.., & Uemoto, S.. (2017). Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer. Annals of Surgical Oncology , 24 , 3732-3740 . http://doi.org/10.1245/s10434-017-6077-y
22) Rawla, Prashanth., Sunkara, T.., & Gaduputi, V.. (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World Journal of Oncology , 10 , 10 - 27 . http://doi.org/10.14740/wjon1166
23) Roy, S.., Srivastava, R. K., & Shankar, S.. (2010). Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. Journal of Molecular Signaling , 5 , 10 - 10 . http://doi.org/10.1186/1750-2187-5-10
24) Wang, Yu., Liang, Yiyi., Xu, Haiyan., Zhang, Xiao., Mao, T.., Cui, Jiujie., Yao, Jiayu., Wang, Yongchao., Jiao, F.., Xiao, Xiuying., Hu, Jiong., Xia, Q.., Zhang, Xiaofei., Wang, Xujun., Sun, Yong-wei., Fu, D.., Shen, Lei., Xu, Xiaojiang., Xue, J.., & Wang, Liwei. (2021). Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discovery , 7 . http://doi.org/10.1038/s41421-021-00271-4
25) Wartenberg, Martin., Cibin, Silvia., Zlobec, I.., Vassella, E.., Eppenberger-Castori, S.., Terracciano, L.., Eichmann, Micha., Worni, M.., Gloor, B.., Perren, A.., & Karamitopoulou, E.. (2018). Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. Clinical Cancer Research , 24 , 4444 - 4454 . http://doi.org/10.1158/1078-0432.CCR-17-3401
26) Waters, Andrew M.., & Der, C.. (2018). KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.. Cold Spring Harbor perspectives in medicine , 8 9 . http://doi.org/10.1101/cshperspect.a031435
27) Witkiewicz, A.., McMillan, E.., Balaji, U.., Baek, GuemHee., Lin, Wan-chi., Mansour, J.., Mollaee, M.., Wagner, K.., Koduru, P.., Yopp, A.., Choti, M.., Yeo, C.., Mccue, P.., White, M.., & Knudsen, E.. (2015). Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nature Communications , 6 . http://doi.org/10.1038/ncomms7744

28) Wood, L.., Canto, M.., Jaffee, E.., & Simeone, D.. (2022). Pancreatic Cancer: Pathogenesis, Screening, Diagnosis and Treatment.. Gastroenterology . http://doi.org/10.1053/j.gastro.2022.03.056
29) Wu, Mengwei., Li, Xiaobin., Zhang, Taiping., Liu, Ziwen., & Zhao, Yupei. (2019). Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer. Frontiers in Oncology , 9 . http://doi.org/10.3389/fonc.2019.00996
30) Yadav, D.., & Lowenfels, A.. (2013). The epidemiology of pancreatitis and pancreatic cancer.. Gastroenterology , 144 6 , 1252-61 . http://doi.org/10.1053/j.gastro.2013.01.068